Comparison of the Expression and Immunogenicity of Wild-Type and Sequence-Modified HIV-1 gag Genes in a Recombinant Sendai Virus Vector

被引:2
作者
Yu, Shuangqing [1 ]
Feng, Xia [1 ]
Shu, Tsugumine [2 ]
Matano, Tetsuro [3 ]
Hasegawa, Mamoru [2 ]
Wang, Xiaoli [4 ]
Li, Hongxia [1 ]
Li, Zelin [4 ]
Zhong, Rugang [4 ]
Zeng, Yi [1 ,4 ]
机构
[1] China CDC, Natl Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 100052, Peoples R China
[2] DNAVEC Corp, Tsukuba, Ibaraki 3050856, Japan
[3] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Tokyo 1088639, Japan
[4] Beijing Univ Technol, Beijing 100022, Peoples R China
关键词
Sendai virus; HIV-1; gag gene; vaccine; T-CELL RESPONSES; IMMUNE-RESPONSES; AIDS VACCINE; IMMUNODEFICIENCY; DNA; BOOST; RNA; REPLICATION; REGIONS; VIREMIA;
D O I
10.2174/157016210791111133
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Efficient expression of HIV-1 structural gene involves regulation by viral Rev and Rev-responsive elements (RRE). Messenger RNAs of wild-type HIV-1 structural genes are either retained in the nucleus or degraded rapidly in the absence of Rev/RRE; therefore little protein can be expressed. Modifying HIV-1 genes is an excellent approach to circumvent this problem, but it is a laborious and costly process. Using certain vectors to deliver wild-type genes may be a promising approach. In this study, the wild-type and modified gag genes, derived from Chinese HIV-1 isolates, were separately constructed in both plasmid DNA and recombinant Sendai virus vectors (rSeV). The expression and immunogenicity of the wild-type and modified gag genes were compared. The results showed that efficient expression of the modified gag gene could be achieved by transfection with DNA and infection with rSeV, but the efficient expression of wild-type gag could only be achieved by rSeV. In addition, the rSeV expressing wild-type gag elicited similar Gag-specific immune responses with modified gag in both SeV/SeV and DNA-prime/rSeV-boost schemes. However, SeV/SeV failed to produce Gag-specific responses as robust as DNA/rSeV. Then the SeV-specific humoral and cellular immune responses were evaluated just before the second rSeV vaccine immunization. It was found that anti-SeV neutralizing antibody was very low but the SeV-specific cellular response was strong. Efficient expression of wild-type HIV-1 structural genes may make the SeV vector a useful tool for the HIV-1 vaccine research, but the strong SeV-specific cellular immune responses may impair the efficacy of SeV-SeV vaccination scheme.
引用
收藏
页码:199 / 206
页数:8
相关论文
共 24 条
  • [11] Robust gag-specific T cell responses characterize viremia control in HIV-2 infection
    Leligdowicz, Aleksandra
    Yindom, Louis-Marie
    Onyango, Clayton
    Sarge-Njie, Ramu
    Alabi, Abraham
    Cotten, Matthew
    Vincent, Tim
    da Costa, Carlos
    Aaby, Peter
    Jaye, Assan
    Dong, Tao
    McMichael, Andrew
    Whittle, Hilton
    Rowland-Jones, Sarah
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (10) : 3067 - 3074
  • [12] A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression
    Li, HO
    Zhu, YF
    Asakawa, M
    Kuma, H
    Hirata, T
    Ueda, Y
    Lee, YS
    Fukumura, M
    Iida, A
    Kato, A
    Nagai, Y
    Hasegawa, M
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (14) : 6564 - 6569
  • [13] [马红霞 MA Hongxia], 2006, [中国生物制品学杂志, Chinese Journal of Biologicals], V19, P365
  • [14] Mata M, 1998, J IMMUNOL, V161, P2985
  • [15] Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial
    Matano, T
    Kobayashi, M
    Igarashi, H
    Takeda, A
    Nakamura, H
    Kano, M
    Sugimoto, C
    Mori, K
    Iida, A
    Hirata, T
    Hasegawa, M
    Yuasa, T
    Miyazawa, M
    Takahashi, Y
    Yasunami, M
    Kimura, A
    O'Connor, DH
    Watkins, DI
    Nagai, Y
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (12) : 1709 - 1718
  • [16] Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen
    Matano, T
    Kano, M
    Nakamura, H
    Takeda, A
    Nagai, Y
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (23) : 11891 - 11896
  • [17] Lytic Granule Loading of CD8+ T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune Control
    Migueles, Stephen A.
    Osborne, Christine M.
    Royce, Cassandra
    Compton, Alex A.
    Joshi, Rohan P.
    Weeks, Kristin A.
    Rood, Julia E.
    Berkley, Amy M.
    Sacha, Jonah B.
    Cogliano-Shutta, Nancy A.
    Lloyd, Margaret
    Roby, Gregg
    Kwan, Richard
    McLaughlin, Mary
    Stallings, Sara
    Rehm, Catherine
    O'Shea, Marie A.
    Mican, JoAnn
    Packard, Beverly Z.
    Komoriya, Akira
    Palmer, Sarah
    Wiegand, Ann P.
    Maldarelli, Frank
    Coffin, John M.
    Mellors, John W.
    Hallahan, Claire W.
    Follman, Dean A.
    Connors, Mark
    [J]. IMMUNITY, 2008, 29 (06) : 1009 - 1021
  • [18] Magnitude and frequency of cytotoxic T-lymphocyte responses: Identification of immunodominant regions of human immunodeficiency virus type 1 subtype C
    Novitsky, V
    Cao, H
    Rybak, N
    Gilbert, P
    McLane, MF
    Gaolekwe, S
    Peter, T
    Thior, I
    Ndung'u, T
    Marlink, R
    Lee, TH
    Essex, M
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (20) : 10155 - 10168
  • [19] Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of gag and gag/protease and particle formation
    Schneider, R
    Campbell, M
    Nasioulas, G
    Felber, BK
    Pavlakis, GN
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (07) : 4892 - 4903
  • [20] Skeletal muscle regeneration after insulin-like growth factor 1 gene transfer by recombinant Sendai virus vector
    Shiotani, A
    Fukumura, M
    Maeda, M
    Hou, X
    Inoue, M
    Kanamori, T
    Komaba, S
    Washizawa, K
    Fujikawa, S
    Yamamoto, T
    Kadono, C
    Watabe, K
    Fukuda, H
    Saito, K
    Sakai, Y
    Nagai, Y
    Kanzaki, J
    Hasegawa, M
    [J]. GENE THERAPY, 2001, 8 (14) : 1043 - 1050